Case Report

Primary Pulmonary Epithelioid Hemangioendothelioma: A Rare Cause of PET-Negative Pulmonary Nodules

Riccardo Cazzuffi,1 Nunzio Calia,1 Franco Ravenna,1 Claudio Pasquini,1 Sara Saturni,1 Giorgio Narciso Cavallesco,2 Francesco Quarantotto,2 Rosa Rinaldi,3 Annaluisa Cogo,1 Gaetano Caramori,1,4 and Alberto Papi1

1 Sezione di Malattie dell’Apparato Respiratorio, Dipartimento di Medicina Clinica e Sperimentale, Università di Ferrara, Italy
2 Dipartimento di Scienze Chirurgiche, AnestesioLogiche e Radiologiche, Modulo di Chirurgia Toracica, Università di Ferrara, Italy
3 Sezione di Anatomia, Istologia e Citologia Patologica, Dipartimento di Medicina Sperimentale e Diagnostica, Università di Ferrara, Italy
4 Centro per lo Studio delle Malattie Infiammatorie Croniche delle Vie Aeree e Patologie Fumo Correlate dell’Apparato Respiratorio (CEMICEF; formerly Centro di Ricerca su Asma e BPCO), Università di Ferrara, Via Savonarola 9, 44121 Ferrara, Italy

Correspondence should be addressed to Gaetano Caramori, gaetano.caramori@unife.it

Received 11 February 2011; Accepted 16 May 2011

Academic Editor: A. Curt

Copyright © 2011 Riccardo Cazzuffi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We report here a case of primary pulmonary epithelioid hemangioendothelioma diagnosed in a 67-year-old Caucasian man, presenting with exertion dyspnoea, dry cough, and multiple bilateral pulmonary nodules revealed by computed tomography. At the 18F-fluorodeoxyglucose positron emission tomography, these nodules were negative. The histopathological diagnosis was made on a pulmonary wedge resection (performed during video-thoracoscopic surgery).

1. Introduction

Pulmonary epithelioid hemangioendothelioma (PEH) is a rare, low- to intermediate-grade tumor of endothelial origin [1] with around 120 cases reported in the literature [2]. At the onset, the patients are usually asymptomatic or present with nonspecific symptoms (such as weight loss, fatigue, dyspnoea, cough, and chest pain). Chest imaging usually shows the presence of multiple, bilateral small pulmonary lesions. The diagnosis usually requires a lung biopsy. The treatment is still not standardized. Surgery is suggested in presence of a solitary nodule or few unilateral nodules. Instead if the lesions are unresectable or multiple and bilateral several chemotherapy protocols have been used. The prognosis is variable with a median survival of 4-5 years.

2. Case Report

A 67-year-old Caucasian man, lifelong nonsmoker, with no prior history of lung diseases, was referred to our university hospital for the presence, in the last 3 months, of exertion dyspnoea (grade 1 according to the Medical Research Council scale [3]) and dry cough. He had worked as an employee without occupational exposures of clinical relevance. His past medical history was characterized by an herniated lumbar disc, systemic arterial hypertension (treated with calcium blockers), diabetes mellitus (treated with oral hypoglycaemic agents), and polycythemia vera (diagnosed in 2007 and treated from 2008 with hydroxyurea). Physical examination was unremarkable. Arterial blood gases analysis performed with the patient breathing room air demonstrated normal values (pH 7.40, PaCO2 43 mmHg, PaO2 91 mmHg, and bicarbonate level 26 mmoL/L). Routine laboratory tests were within the normal range except for those listed in Table 1. Serum levels of neoplastic markers were within normal range, including carcinoembryonic antigen (2.7 ng/mL), prostate-specific antigen (3.75 ng/mL), and CA19.9 (15 U/mL). Also the serum levels of angiotensin-converting enzyme (11 IU/mL) and β2 microglobulin (2.50 mg/mL) were within normal limits.
Table 1: Laboratory tests concerning diabetes mellitus and polycythemia vera.

| Test                     | Value   | Normal Range               |
|--------------------------|---------|----------------------------|
| White blood cells        | 12.01 × 10³ | Normal range 4.00–11 × 10³/μL |
| Red blood cells          | 4.80 × 10⁴  | Normal range 4.50–6.50 × 10⁴/μL |
| HGB                      | 15.9    | Normal range 13.0–18 g/dl   |
| HCT                      | 49      | Normal range 40–54%         |
| MCV                      | 103     | Normal range 76–96 fl       |
| MCH                      | 33.1    | Normal range 27.0–32.0 pg/dl|
| MCHC                     | 32.3    | Normal range 30.0–35.0 g/dl |
| PLT                      | 434     | Normal range 150–450 × 10³/μL|
| Blood neutrophils        | 9.56 × 10³ | Normal range 2.00–7.50 × 10³/μL |
| Blood lymphocytes        | 1.92 × 10³ | Normal range 1.50–5.00 × 10³/μL |
| Blood monocytes          | 0.43 × 10³ | Normal range 0.20–1.00 × 10³/μL |
| Blood eosinophils        | 0.08 × 10³ | Normal range 0.04–0.40 × 10³/μL |
| Blood basophils          | 0.01 × 10³ | /                           |
| PT                       | 1.09    | Normal range 0.85–1.20 INR  |
| APTT                     | 1.22    | Normal range 0.85–1.20 ratio|
| Glycaemia                | 99      | Normal range 70–11 mg/dl    |
| Creatinine               | 1.2     | Normal range 0.9–1.4 mg/dl  |

APTT: Activated thromboplastin time. HCT: Hematocrit. HGB: Haemoglobin. LDH: Lactate dehydrogenase. MCH: Mean corpuscular Haemoglobin. MCV: Mean blood cell volume. MCHC: Mean cell haemoglobin concentration. PLT: Platelets. PT: Prothrombin time.

The pulmonary function tests showed the presence of a restrictive pattern with a vital capacity (VC) of 3.14 litres (70% of the predicted value), a forced vital capacity (FVC) of 3.11 litres (72% of the predicted value), forced expiratory volume in one second (FEV₁) of 2.55 litres (76.5% of predicted value), a FEV₁/VC ratio of 81% (108% of the predicted value) and a total lung capacity (TLC), 5.35 litres (73.3% of the predicted value). DLCO was in the normal range (Figure 1).

The chest radiography and a computed tomography of the chest (performed with iodine intravenous contrast medium) showed the presence of multiple bilateral pulmonary nodules (with a diameter variable between 3 mm and 3 cm) without contrast enhancement and the presence of one nodule (with the diameter of 2 cm) in the fourth hepatic segment showing late-phase contrast enhancement and another in the spleen (with the diameter of 1 cm) with cystic features (Figure 2).

Interestingly, at the 18F-fluorodeoxyglucose positron emission tomography (PET), all these nodules were not showing any uptake of the tracer (Figure 3).

The fiberoptic bronchoscopy was normal. A transbronchial lung biopsy and an ultrasound-guided transthoracic lung biopsy were both nondiagnostic.

The final diagnosis of pulmonary epithelioid hemangiendothelioma was made by pulmonary wedge resection of a nodule located in the left lower lobe by video-thoracoscopic surgery. Histopathological examination of the resected tissue revealed round- to oval-shaped nodules, with a central sclerotic, hypocellular zone, and peripheral zone rich of cells. There was tumour diffusion into the adjacent bronchioles and the alveolar spaces with micropolyloid aspects. The extracellular stroma consisted of an abundant matrix of chondroid, hyaline, mucinous, or myxomatous appearance.

The neoplastic cells were of polygonal shape and eosinophilic with round nuclei and uniform small to moderately sized nucleoli. Some cells had cytoplasmic vacuoles.

Immunohistochemical studies demonstrated that the neoplastic cells are endothelial cells immunoreactive for Von Willebrand factor, CD31, CD34, and vimentin (Figure 4). Immunostaining for other markers (including caudal type homeobox transcription factor 2 (CDX2), cytokeratin (CK) 20, CK7, prostate-specific antigen (PSA), pan-cytokeratin, chromogranin, epithelial membrane antigen (EMA), HMB45, progesterone receptor, and thyroid transcription factor (TTF)-1) was negative.
Figure 2: The chest radiography (a, b) and a computed tomography of the chest (performed with iodine intravenous contrast medium) (c, d) showed the presence of multiple bilateral pulmonary nodules.

3. Discussion

Pulmonary epithelioid hemangioendothelioma (PEH) is a rare, low- to intermediate-grade tumor of endothelial origin [1]. Epithelioid hemangioendothelioma can arise from many organs, including lungs, liver, bone, and soft tissue, simultaneously or sequentially. When this occurs, it may be difficult to determine if the tumor is multicentric from the beginning or there is a primary lesion with metastases to the other tissues [4]. Around 120 cases have been reported in literature [2, Table 2], only five of them were in Italian patients [5, 15–18]. Mean (SD) age of patients is 40.1 (17.5) years, and 73% are females [6]. Interestingly, our patient is instead a 67-year-old male. Most patients are asymptomatic at presentation, and some are complaining of weight loss, fatigue, dyspnoea, fever, pleuritic chest pain, mild nonproductive cough, and haemoptysis [19]. In most cases, the physical examination is normal, but few cases of digital clubbing and pleural effusions have been reported [1, 6].

The most characteristic feature of PEH on chest radiographs or CT is the presence of multiple perivascular nodules with well- or ill-defined margins in both lungs. The nodules may range in size up to 2 cm, but most of them are ≤1 cm in diameter; they are usually found near medium-sized vessels and bronchi [1]. This radiological presentation is suggestive of many lung diseases (Table 3).

Some authors consider 18F-fluorodeoxyglucose positron emission tomography an important tool for PEH diagnosis [7]; however, in our patient, the PET was negative, suggesting that a negative PET cannot exclude PEH. Unfortunately, we do not have a molecular explanation for this finding but may be related to a low proliferation rate of the neoplastic cells.

The diagnosis of PEH is made on the basis of the histopathological features and confirmed using immunohistochemical staining for endothelial cell markers, such as against factor VIII-related von Willebrand antigen, CD31 or CD34 [2, 4, 13, 20, 21].

The prognosis is variable. The 5-year survival is around 60% (range 47–71%). In fact, there are two groups of PEH at the clinical presentation: (1) one asymptomatic, with a solitary pulmonary nodule or unilateral multiple nodules. Usually they can be managed with surgery alone, and lymphatic invasion is unlikely. Their prognosis is good with a median survival of more than 10 years; (2) another symptomatic group presents with multiple bilateral pulmonary nodules or pleural effusion with scarce response to chemotherapy. The prognosis of this group is poor [11]. Most patients die from pulmonary insufficiency as a result of an increasing number of tumor nodules [9]. Hematogeneous metastases are rare and have been described especially in the liver but also in other sites [2, 4].
Figure 3: 18F-fluorodeoxyglucose positron emission tomography, all these nodules were not showing any uptake of the tracer.

Table 2: Review of the clinical, radiological and pathological features of the published cases of primary pulmonary epithelioid heman-gioendothelioma.

| Review of the literature | Our case report |
|--------------------------|---------------|
| Female/male ratio        | 3 : 1 female  |
|                          | Male          |
| Mean (SD) age            | 40.1 (17.5) years |
|                          | 67 years      |
| Symptoms                 | Weight loss, fatigue, and respiratory symptoms (dyspnoea, chest pain, mild nonproductive cough, and mild haemoptysis) |
|                          | Dyspnoea and dry cough |
| Chest radiography and computed tomography | Usually multiple bilateral pulmonary nodules |
|                          | Multiple bilateral pulmonary nodules |
| PET                      | Positive      |
|                          | Negative      |
| Metastatic sites         | Lymph nodes, liver, bone, skin, serosal membranes, spleen, tonsils, retroperitoneum, kidney and central nervous system |
|                          | Single spleen and liver metastatic nodules |
| Immunohistochemical features | Factor VIII von Willebrand factor+, CD31+, or CD34+ |
|                          | Factor VIII von Willebrand factor+, CD31+, CD34+ |
| 5-year survival (%)      | 60%           |
|                          | Alive for eight months then lost at the follow up |

Obtained with the data from [4–18].
**Figure 4:** (a) Neoplastic nodule showing increased number of cells at the periphery with an eosinophilic stroma (H/E, 100x magnification). (b) The neoplastic cells are of polygonal shape and eosinophilic with round nuclei and uniform small to moderately sized nucleoli. (H/E, 200x magnification). (c) Immunoperoxidase staining for CD34 of the neoplastic cells (brown colour) (200x magnification). (d) Immunoperoxidase staining for CD31 of the neoplastic cells (brown colour) (200x magnification).

**Table 3:** Differential diagnosis of multiple pulmonary bilateral nodules.

| Diagnosis                                      |
|-----------------------------------------------|
| Metastases                                     |
| Primary lung cancer (particularly bronchioloalveolar carcinoma) |
| Lymphoid tumors and myeloma                   |
| Leukaemic infiltrates                         |
| Benign vascular tumors (hemangioma and lymphangioma) |
| Malignant vascular tumors (angiosarcoma and Kaposi’s sarcoma) |
| Neuroendocrine tumourlets                      |
| Nodular lesions in pulmonary fibrosis         |
| Pneumoconiosis                                 |
| Infections (tuberculosis, nocardiosis, aspergillosis, and histoplasmosis) |
| Sarcoïdosis                                    |
| Langerhan’s cell histiocytosis                 |
| Vasculitis                                     |
| Connectivitis                                  |
| Pulmonary arteriovenous malformations          |

Obtained with the data from [4, 5, 9, 12–14].

The treatment of PEH is not standardized. Surgery alone is indicated in the presence of a single pulmonary nodule or unilateral multiple nodules. Lung transplantation should be considered in patients with vascular infiltration [10].

Various chemotherapies have been reported for unresectable or metastatic PEH, with variable effectiveness [22]. Other authors have suggested a role for the hormonal therapy (antiestrogens and progesterone) in patients with diffuse disease if the neoplastic cells express estrogen and progesterone receptors [23]. A slight regression of the pulmonary lesions was also obtained with interferon (IFN)-2α, probably for its antiangiogenic activity [24]. Thalidomide and IFN-α have also been proposed for unresectable cases [22]. Some beneficial results were also obtained with bevacizumab, a monoclonal antibody that blocks human VEGF-A [22, 25]. The neoplastic cells express glucocorticoid receptors and the enzyme 11β-hydroxysteroid dehydrogenase involved in the synthesis of the steroids, suggesting a potential role for steroid modulators [26].

In conclusion, we had the opportunity to observe an unusual primary pulmonary hemangioepithelioma in an old
male patient, and interestingly, in comparison with the published literature, the neoplastic lesions were PET negative. Again, as previously suggested [27], we stress the importance of starting an international clinical registry of this unusual neoplasm.

**Acknowledgment**

Riccardo Cazzuffi and Gaetano Caramori have equally contributed to this work.

**References**

[1] H. Baba, M. Tomiyasu, H. Makino, A. Yamamoto, H. Yokoyama, and Y. Oshiro, “Surgical resection of a primary pulmonary epithelioid hemangioendothelioma in bilateral lungs,” *General Thoracic and Cardiovascular Surgery*, vol. 58, no. 8, pp. 431–433, 2010.

[2] O. Leleu, F. Lenglet, C. Clarot, P. Kleinmann, and V. Jounieaux, “Pulmonary epithelioid haemangioendothelioma: reports of three cases and a review of the literature,” *Revue des Maladies Respiratoires*, vol. 27, no. 7, pp. 778–783, 2010.

[3] J. C. Bestall, E. A. Paul, R. Garrod, R. Garnham, P. W. Jones, and J. A. Wedzicha, “Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease,” *Thorax*, vol. 54, no. 7, pp. 581–586, 1999.

[4] B. Ye, W. Li, X. Y. Liu et al., “Multiple organ metastases of pulmonary epithelioid haemangioendothelioma and a review of the literature,” *Medical Oncology*, vol. 27, no. 1, pp. 49–54, 2010.

[5] G. A. Rossi, P. Tomà, O. Sacco et al., “A 14-yr-old male with dyspnoea, productive cough and chest pain,” *European Respiratory Journal*, vol. 22, no. 2, pp. 387–391, 2003.

[6] R. M. S. Amin, K. Hiroshima, T. Kokubo et al., “Risk factors and independent predictors of survival in patients with pulmonary epithelioid haemangioendothelioma. Review of the literature and a case report,” *Respirology*, vol. 11, no. 6, pp. 818–825, 2006.

[7] S. Watanabe, E. Yano, T. Kita et al., “18F-FDG-PET/CT as an indicator for resection of pulmonary epithelioid hemangioendothelioma,” *Annals of Nuclear Medicine*, vol. 22, no. 6, pp. 521–524, 2008.

[8] N. Toghi, K. Tsuta, A. M. Maeshima et al., “Malignant pulmonary epithelioid hemangioendothelioma with hilar lymph node metastasis,” *Annals of Diagnostic Pathology*, vol. 15, no. 3, pp. 207–212, 2011.

[9] T. Schattenberg, R. Kam, M. Klopp et al., “Pulmonary epithelioid hemangioendothelioma: report of three cases,” *Surgery Today*, vol. 38, no. 9, pp. 844–849, 2008.

[10] P. Bagam, M. Hassan, F. L. P. Barthes et al., “Prognostic factors and surgical indications of pulmonary epithelioid hemangioendothelioma: a review of the literature,” *Annals of Thoracic Surgery*, vol. 82, no. 6, pp. 2010–2013, 2006.

[11] Y. Özcanmouni, M. Bouchikh, A. Achi et al., “Pulmonary epithelioid hemangioendothelioma: a case report,” *Cases Journal*, vol. 2, no. 9, article no. 8235, 2009.

[12] L. Azcarate Perea, E. Oliveros Abece, N. Moreno Mata, R. Salomón Pérez, E. Villalta Castel, and F. González Aragoneses, “Pulmonary epithelioid hemangioendothelioma,” *Archivos de Bronconeumología*, vol. 45, no. 9, pp. 466–468, 2009.

[13] A. Weissferdt and C. A. Moran, “Primary vascular tumors of the lungs: a review,” *Annals of Diagnostic Pathology*, vol. 14, no. 4, pp. 296–308, 2010.

[14] N. J. Mayer, W. A. H. Wallace, and H. H. Kamel, “Nodular lesions of the lung: a practical approach to histological diagnosis,” *Current Diagnostic Pathology*, vol. 9, no. 3, pp. 188–198, 2003.

[15] V. Poletti, “Epithelioid haemangioendothelioma of the lung mimicking clinical features of pulmonary histiocytosis X,” *Monaldi Archives for Chest Disease*, vol. 52, no. 4, pp. 346–348, 1997.

[16] G. Paciocco, U. Caterino, and D. D’Auria, “Epithelioid haemangioendothelioma of the lung: a high malignancy case,” *Monaldi Archives for Chest Disease*, vol. 54, no. 3, pp. 231–233, 1999.

[17] A. Sortini, M. Santini, P. Carcoforo, D. Sortini, E. Pozza, and I. Donini, “Primary lung epithelioid hemangioendothelioma with multiple bilateral metastatic localizations: case report and review,” *International Surgery*, vol. 85, no. 4, pp. 336–338, 2000.

[18] F. Massera, R. Delfanti, G. Rocco, P. Antonelli, M. Donghi, and M. Robustellini, “Pulmonary epithelioid haemangioendothelioma mimicking bronchogenic carcinoma,” *Journal of Cardiovascular Surgery*, vol. 45, no. 4, pp. 397–398, 2004.

[19] J. J. Erasmus, H. P. McAdams, and M. S. Carraway, “A 63-year-old woman with weight loss and multiple lung nodules,” *Chest*, vol. 111, no. 1, pp. 236–238, 1997.

[20] M. Miettinen, A. E. Lindenmayer, and A. Chabaul, “Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens—evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor,” *Modern Pathology*, vol. 7, no. 1, pp. 82–90, 1994.

[21] W. D. Travis, E. Brambilla, H. K. Mueller-Hermelink, and C. C. Harris, *Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart*, WHO Classification of Tumours, IARC Press, Lyon, France, 2004.

[22] L. Belmont, L. Zemoura, and L. J. Couderc, “Pulmonary epithelioid haemangioendothelioma and bevacizumab,” *Journal of Thoracic Oncology*, vol. 3, no. 5, pp. 557–558, 2008.

[23] N. P. Ohori, S. A. Yousem, E. Sonmez-Alpan, and T. V. Colby, “Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung,” *American Journal of Clinical Pathology*, vol. 96, no. 4, pp. 529–535, 1991.

[24] E. Radzikowska, E. Szczepulska-Wójcik, M. Chabowski, K. Onisz, R. Langfort, and K. Roszkowski, “Pulmonary epithelioid hemangioendothelioma—interferon 2-alpha treatment—case report,” *Pneumonologia i Alergologia Polska*, vol. 76, no. 4, pp. 281–285, 2008.

[25] Y. H. Kim, S. A. Yousem, E. Sonmez-Alpan, and T. V. Colby, “Expression of glucocorticoid receptor and 11β hydroxysteroid dehydrogenase in a case of pulmonary epithelioid haemangioendothelioma,” *Molecular Pathology*, vol. 55, no. 1, pp. 61–64, 2002.

[26] J. Kpodou, C. Tshibaka, and M. G. Massad, “The importance of clinical registries for pulmonary epithelioid haemangioendothelioma,” *Chest*, vol. 127, no. 5, pp. 1870–1871, 2005.